Brief Title: Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Number of subjects with Dose-limiting toxicities(DLTs) in Part A

Primary Outcome 1 - Timeframe: Up to 21 days

Primary Outcome 2 - Measure: Number of subjects with treatment-emergent adverse events (TEAEs) in Part A

Primary Outcome 2 - Timeframe: Up to 5 months

Primary Outcome 3 - Measure: Number of subjects with drug-related TEAEs in Part A

Primary Outcome 3 - Timeframe: Up to 5 months

Primary Outcome 4 - Measure: Number of subjects with treatment-emergent serious adverse events(TESAEs) in Part A

Primary Outcome 4 - Timeframe: Up to 5 months

Primary Outcome 5 - Measure: Progression Free Survival(PFS)

Primary Outcome 5 - Timeframe: Up to 25 months

CONDITION

• Urothelial Carcinoma

ELIGIBILITY

Inclusion criteria:
Existence of archival or fresh tumor biopsy specimen for FGFR1/3 mRNA expression testing

- High FGFR1 or 3 mRNA expression levels (RNAscope score of 3+ or 4+) in archival or fresh tumor biopsy specimen

- Documented locally advanced (T4, any N; or any T, N2-3) or metastatic urothelial carcinoma (transitional cell carcinoma) including urinary bladder, renal pelvis, ureters, urethra, meeting all of the following criteria:

- No prior systemic treatment for locally advanced or metastatic urothelial carcinoma. For patients who received prior adjuvant/neoadjuvant chemotherapy or chemo-radiation for urothelial carcinoma, a treatment-free interval > 12 months between the last treatment administration and the date of recurrence is required in order to be considered treatment-naïve in the metastatic setting. Prior local intra-vesical chemotherapy or prior local immunotherapy is allowed if completed at least 4 weeks before the first study drug administration. Regionally available standard of care options must be considered for all patients.
Ineligibility for cisplatin-based chemotherapy as defined by any one of the following criteria:
Impaired renal function (GFR > 30 but < 60 mL/min/1.73 m2) according to the modification of diet in renal disease (MDRD) abbreviated formula - A Hearing loss (measured by audiometry) of > 25 dB at two contiguous test frequencies in at least one ear.

- Grade ≥ 2 peripheral neuropathy (i.e. sensory alteration or paresthesia including tingling)

- Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1.
Exlusion criteria:
Active symptomatic or untreated brain metastases as determined by CT or MRI evaluation during screening and prior radiographic assessment.

- History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with anti-phospholipid syndrome, granulomatosis with polyangiitis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.
History or current condition of an uncontrolled cardiovascular disease including any of the following conditions:
Congestive heart failure (CHF) NYHA Class 2 or greater, unstable angina (symptoms of angina at rest) or

- New-onset angina (within last 3 months before the first study drug administration)

- Myocardial infarction (MI) within past 6 months before the first study drug administration

- Unstable cardiac arrhythmias requiring anti-arrhythmic therapy.

- Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or known left ventricular ejection fraction < 50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate. - Current diagnosis of any retinal disorders including retinal detachment, retinal pigment epithelial detachment (RPED), serous retinopathy or retinal vein occlusion. - Current evidence of endocrine alteration of calcium phosphate homeostasis (e.g. parathyroid disorder, history of parathyroidectomy, tumor lysis, tumoral calcinosis, paraneoplastic hypercalcemia). - Concomitant therapies that are known to increase serum calcium or phosphate levels (i.e. antacids, phosphate-containing laxatives oral/rectal, potassium phosphate) and that cannot be discontinued or switched to a different medication before the first study drug administration - Treatment with systemic corticosteroids or other systemic immunosuppressant medications within 2 weeks before the first study drug administration, or anticipated requirement for systemic immunosuppressive medications during the trial.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: N/A

Role: N/A

Affiliation: N/A

Overall Contact

Name: N/A

Phone: (+) 1-888-8422937

Email: clinical-trials-contact@bayer.com

LOCATION